VistaGen Therapeutics (VTGN) Stock Price, News & Analysis

Company Overview

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain. VistaGen also develops PH-10, a topical neuroactive small molecule in clinical development for psoriasis and atopic dermatitis. To broaden its development reach, VistaGen has entered strategic partnerships, including a licensing agreement with Yuhan Corporation for AV-101 in South Korea, and continues to advance its clinical and regulatory strategy primarily in North America and Asia.

VistaGen’s proprietary Human Clinical Drug Rescue and ReRationalization platform employs patient-derived pluripotent stem cell–derived neural and cardiac cells to predict clinical efficacy and safety, reduce late-stage development risk and complement traditional preclinical models. This platform supports both in-house pipeline programs and collaborative research initiatives. Leading the company is President and Chief Executive Officer Shawn K. Singh, who has overseen VistaGen’s research and corporate development efforts since joining in 2014 and remains committed to translating innovative science into new therapeutic options for underserved patient populations.

Key Stats

• Today's Range: $0.59 to $0.61
• 50-Day Range: $0.54 to $0.65
• 52-Week Range: $0.43 to $5.14
• Volume: 166,788 shs
• Average Volume: 892,254 shs
• Market Capitalization: $23.30 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $0.95
• Consensus Rating: Reduce

VistaGen Therapeutics Stock Analysis - MarketRank™

VistaGen Therapeutics scored higher than 37% of companies evaluated by MarketBeat, and ranked 540th out of 857 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.9 / 5
• Analyst Rating: Reduce

Consensus Rating

VistaGen Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.80, and is based on no strong buy ratings, no buy ratings, 4 hold ratings, and 1 sell rating.

Upside Potential

VistaGen Therapeutics has a consensus price target of $0.95, representing about 59.7% upside from its current price of $0.60.

Amount of Analyst Coverage

VistaGen Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for VistaGen Therapeutics are expected to grow in the coming year, from ($1.88) to ($1.31) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of VistaGen Therapeutics is -0.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of VistaGen Therapeutics is -0.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

VistaGen Therapeutics has a P/B Ratio of 0.24. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.45% of the float of VistaGen Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

VistaGen Therapeutics has a short interest ratio ("days to cover") of 2.72, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in VistaGen Therapeutics has recently increased by 21.33%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

VistaGen Therapeutics does not currently pay a dividend.

Dividend Growth

VistaGen Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for VistaGen Therapeutics this week, compared to 5 articles on an average week.

Search Interest

3 people have searched for VTGN on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added VistaGen Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, VistaGen Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.85% of the stock of VistaGen Therapeutics is held by insiders.

Percentage Held by Institutions

78.39% of the stock of VistaGen Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

VTGN Stock Analysis - Frequently Asked Questions

How have VTGN shares performed this year?

VistaGen Therapeutics' stock was trading at $0.6619 at the beginning of the year. Since then, VTGN shares have decreased by 10.1% and is now trading at $0.5950.

How were VistaGen Therapeutics' earnings last quarter?

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) posted its quarterly earnings results on Thursday, February, 12th. The company reported ($0.45) EPS for the quarter, beating analysts' consensus estimates of ($0.51) by $0.06. The company had revenue of $0.30 million for the quarter, compared to analyst estimates of $0.14 million.
Read the conference call transcript.

When did VistaGen Therapeutics' stock split?

VistaGen Therapeutics's stock reverse split on Wednesday, June 7th 2023.The 1-30 reverse split was announced on Wednesday, June 7th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Who are VistaGen Therapeutics' major shareholders?

Top institutional shareholders of VistaGen Therapeutics include AdvisorShares Investments LLC (0.70%).
View institutional ownership trends.

How do I buy shares of VistaGen Therapeutics?

Shares of VTGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of VistaGen Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that VistaGen Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), CrowdStrike (CRWD), Adobe (ADBE), Advanced Micro Devices (AMD) and Arista Networks (ANET).

Company Calendar

• Last Earnings: 2/12/2026
• Today: 5/07/2026
• Next Earnings (Estimated): 6/16/2026
• Fiscal Year End: 3/31/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:VTGN
• CIK: 1411685
• Web: www.vistagen.com
• Phone: (650) 577-3600
• Fax: 888-482-2602
• Employees: 40
• Year Founded: 1998

Price Target and Rating

• Average Price Target for VistaGen Therapeutics: $0.95
• High Price Target: $1.00
• Low Price Target: $0.90
• Potential Upside/Downside: +59.7%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.89)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$51.42 million
• Net Margins: N/A
• Pretax Margin: -8,486.84%
• Return on Equity: -109.72%
• Return on Assets: -89.62%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.67
• Quick Ratio: 4.67

Sales & Book Value

• Annual Sales: $490 thousand
• Price / Sales: 48.11
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.44 per share
• Price / Book: 0.24

Miscellaneous

• Outstanding Shares: 39,620,000
• Free Float: 38,491,000
• Market Cap: $23.57 million
• Optionable: Optionable
• Beta: 0.31